Everolimus in Refractory Testicular Germ Cell Cancer

Summary

Everolimus in refractory testicular germ cell cancer. Everolimus 10 mg /day/ is administered to the patient until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements. Feasibility of surgical resection will be assessed after every 2 cycles of the treatment in patients with partial response.

Timeline

Start

2011-11

Primary completion

2015-06

Completion

2015-06

Drugs

Indications